vs
COASTAL FINANCIAL CORP（CCB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是COASTAL FINANCIAL CORP的1.6倍（$219.9M vs $138.0M），Orthofix Medical Inc.同比增速更快（2.0% vs -5.8%），COASTAL FINANCIAL CORP自由现金流更多（$246.1M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -3.6%）
富达国民金融是美国财富500强企业，面向房地产与按揭行业提供产权保险及交割服务。2019年，其产权及房地产业务相关年营收约为84.69亿美元，是行业内具有领先地位的金融服务提供商。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CCB vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.6倍
$138.0M
营收增速更快
OFIX
高出7.7%
-5.8%
自由现金流更多
CCB
多$229.3M
$16.8M
两年增速更快
OFIX
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $138.0M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 12.4% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | -5.8% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.84 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCBOFIX
| Q4 25 | $138.0M | $219.9M | ||
| Q3 25 | $144.7M | $205.6M | ||
| Q2 25 | $119.4M | $203.1M | ||
| Q1 25 | $139.5M | $193.6M | ||
| Q4 24 | $146.5M | $215.7M | ||
| Q3 24 | $151.1M | $196.6M | ||
| Q2 24 | $135.3M | $198.6M | ||
| Q1 24 | $148.4M | $188.6M |
净利润CCBOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $13.6M | $-22.8M | ||
| Q2 25 | $11.0M | $-14.1M | ||
| Q1 25 | $9.7M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $13.5M | $-27.4M | ||
| Q2 24 | $11.6M | $-33.4M | ||
| Q1 24 | $6.8M | $-36.0M |
毛利率CCBOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率CCBOFIX
| Q4 25 | 12.4% | 0.2% | ||
| Q3 25 | 12.4% | -8.3% | ||
| Q2 25 | 12.0% | -7.9% | ||
| Q1 25 | 8.4% | -25.2% | ||
| Q4 24 | 11.7% | -5.3% | ||
| Q3 24 | 10.8% | -9.6% | ||
| Q2 24 | 11.1% | -12.5% | ||
| Q1 24 | 5.9% | -15.6% |
净利率CCBOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 9.4% | -11.1% | ||
| Q2 25 | 9.2% | -6.9% | ||
| Q1 25 | 7.0% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 8.9% | -13.9% | ||
| Q2 24 | 8.6% | -16.8% | ||
| Q1 24 | 4.6% | -19.1% |
每股收益（稀释后）CCBOFIX
| Q4 25 | $0.84 | $-0.05 | ||
| Q3 25 | $0.88 | $-0.57 | ||
| Q2 25 | $0.71 | $-0.36 | ||
| Q1 25 | $0.63 | $-1.35 | ||
| Q4 24 | $0.95 | $-0.76 | ||
| Q3 24 | $0.97 | $-0.71 | ||
| Q2 24 | $0.84 | $-0.88 | ||
| Q1 24 | $0.50 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.0M | $450.0M |
| 总资产 | $4.7B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCBOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务CCBOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益CCBOFIX
| Q4 25 | $491.0M | $450.0M | ||
| Q3 25 | $475.3M | $442.5M | ||
| Q2 25 | $461.7M | $458.3M | ||
| Q1 25 | $449.9M | $458.3M | ||
| Q4 24 | $438.7M | $503.1M | ||
| Q3 24 | $331.9M | $525.9M | ||
| Q2 24 | $316.7M | $546.0M | ||
| Q1 24 | $303.7M | $570.3M |
总资产CCBOFIX
| Q4 25 | $4.7B | $850.6M | ||
| Q3 25 | $4.6B | $832.6M | ||
| Q2 25 | $4.5B | $837.2M | ||
| Q1 25 | $4.3B | $823.1M | ||
| Q4 24 | $4.1B | $893.3M | ||
| Q3 24 | $4.1B | $867.9M | ||
| Q2 24 | $4.0B | $882.0M | ||
| Q1 24 | $3.9B | $906.0M |
负债/权益比CCBOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $254.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $246.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 178.3% | 7.6% |
| 资本支出强度资本支出/营收 | 6.1% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $436.4M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CCBOFIX
| Q4 25 | $254.6M | $27.7M | ||
| Q3 25 | $59.0M | $12.4M | ||
| Q2 25 | $66.0M | $11.6M | ||
| Q1 25 | $71.7M | $-18.4M | ||
| Q4 24 | $259.8M | $23.7M | ||
| Q3 24 | $62.6M | $11.7M | ||
| Q2 24 | $72.1M | $9.0M | ||
| Q1 24 | $56.8M | $-18.6M |
自由现金流CCBOFIX
| Q4 25 | $246.1M | $16.8M | ||
| Q3 25 | $57.4M | $2.5M | ||
| Q2 25 | $64.0M | $4.5M | ||
| Q1 25 | $68.9M | $-25.1M | ||
| Q4 24 | $249.9M | $15.2M | ||
| Q3 24 | $60.2M | $6.3M | ||
| Q2 24 | $69.5M | $-360.0K | ||
| Q1 24 | $55.0M | $-29.1M |
自由现金流率CCBOFIX
| Q4 25 | 178.3% | 7.6% | ||
| Q3 25 | 39.7% | 1.2% | ||
| Q2 25 | 53.6% | 2.2% | ||
| Q1 25 | 49.4% | -13.0% | ||
| Q4 24 | 170.6% | 7.0% | ||
| Q3 24 | 39.8% | 3.2% | ||
| Q2 24 | 51.3% | -0.2% | ||
| Q1 24 | 37.1% | -15.4% |
资本支出强度CCBOFIX
| Q4 25 | 6.1% | 4.9% | ||
| Q3 25 | 1.2% | 4.8% | ||
| Q2 25 | 1.7% | 3.5% | ||
| Q1 25 | 2.0% | 3.5% | ||
| Q4 24 | 6.8% | 4.0% | ||
| Q3 24 | 1.6% | 2.7% | ||
| Q2 24 | 1.9% | 4.7% | ||
| Q1 24 | 1.2% | 5.6% |
现金转化率CCBOFIX
| Q4 25 | — | — | ||
| Q3 25 | 4.34× | — | ||
| Q2 25 | 5.99× | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.65× | — | ||
| Q2 24 | 6.22× | — | ||
| Q1 24 | 8.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
